On December 12, EY announced the winners of the EY Entrepreneur Of The Year 2023. Jiang Rensheng, Secretary of the Party Committee, Chairman and President of Zhifei Biotech, won the "Ernst & Young Entrepreneur Of The Year Award - Life Science and Healthcare Industry Award".
Ernst & Young.
The EY Entrepreneur Of The Year is one of the world's most prestigious international business awards, first held in China in 2006. Winners are selected by an independent panel of social and business leaders, experts and past EY Entrepreneur Of The Year winners.
Ernst & Young.
With the theme of "Creating Opportunities through Integration", the EY Entrepreneur Of The Year 2023 aims to recognize outstanding entrepreneurs who uphold the spirit of openness and cooperation and contribute to the promotion of Chinese-style modernization and high-quality economic development.
On December 12, Li Zhenjing, Vice President and Chief Financial Officer of Zhifei, attended the award ceremony. Ernst & Young.
Since its establishment, under the leadership of Chairman Jiang Rensheng, Zhifei has always adhered to the tenet of "social benefits first, enterprise benefits second", implemented the two-wheel drive development model of "technology & market", embarked on a unique path of high-quality development, and has developed into one of the leading enterprises in the industry, and is now forging ahead in the direction of a world-class biopharmaceutical company.
The company will achieve an operating income of 382 in 20226.4 billion yuan, tax payment 611.1 billion yuan;In the first three quarters of 2023, the operating income was 3927.1 billion yuan, tax payment 597.8 billion yuan, with a cumulative tax payment of more than 22 billion yuan. Nearly 9,000 people have been employed in the Zhifei system (including shareholding companies), making positive contributions to social and economic development.
In the future, Zhifei Biotech will continue to adhere to the mission of "preventing and curing existing diseases and protecting human health".
1. Focus on and professionally deepen the field of biopharmaceuticals, show more responsibility in the construction of "Healthy China", and contribute more to the promotion of Chinese-style modernization.
Disclaimer: This article is for informational purposes only and does not constitute investment advice.